INTRODUCTION
============

Pharmacogenomics focuses on how individual genetic variations influence drug responses, and is helping to develop safer and more effective treatments for patients ([@b23-bt-25-482]). Many pharmacogenomic studies have concerned single nucleotide polymorphisms (SNPs) that affect drug responses, and several SNPs have been reported ([@b10-bt-25-482]). However, the diversity of drug responses is not explained by genetic mutation alone. As well as the genetic polymorphisms, drug response may be different due to factors that regulate gene expression.

MicroRNAs (miRNAs) are small, ∼21 nucleotide single-strand noncoding RNAs that can regulate gene expression by binding to partially complementary sites in 3′ untranslated regions (3′ UTRs) of messenger RNAs (mRNAs). This miRNA-mRNA interaction governs a variety of mechanisms that control gene expression, including mRNA degradation and translational repression ([@b32-bt-25-482]; [@b22-bt-25-482]). The mRNAs affected by the miRNAs consequently influence susceptibility to cancer, as well as amentia, autoimmune diseases, and diabetes ([@b26-bt-25-482]). Therefore, miRNAs are becoming recognized as important mediators that affect drug responses, without affecting the genomic sequence. An increasing number of studies on pharmacoepigenetics and pharamcoepigenomics support a role for miRNA in regulating expression of genes encoding proteins involved in drug absorption, distribution, metabolism, and excretion (ADME) ([@b27-bt-25-482]; [@b25-bt-25-482]), as well as pharmacodynamics ([@b38-bt-25-482]). One miRNA can regulate various ADME genes via direct and/or indirect targeting, or one ADME gene may be modulated by multiple miRNAs ([@b39-bt-25-482]). However, our current understanding of miRNA action was mainly obtained from *in vitro* cell culture systems and *ex vivo* systems ([@b25-bt-25-482]). Moreover, prediction and identification of miRNAs target genes is a time-consuming, labor-intensive, and errorprone process ([@b12-bt-25-482]).

This epigenetic regulation of miRNAs in drug transporters or enzymes has a greater impact on drug responses. The influence of the epigenetic changes in cancer diseases can be expected to be even greater. Thus, we hypothesized that the drug response may be affected by expression changes of pharmacogenes in patients with cancer, in special, in organs involved in drug metabolism. The Cancer Genome Atlas (TCGA) Research Network has profiled and analyzed large numbers of human tumors to discover molecular aberrations at the DNA, RNA, and protein level, and also examined epigenetic changes, including those related to miRNA ([@b31-bt-25-482]). Because the TCGA also contains a significant collection of normal tissue samples, it would be an appropriate resource for pharmacogenomic miRNA studies. Tumor-induced miRNA changes are also important in drug responses and toxicity, especially responses to chemotherapy ([@b40-bt-25-482]).

Therefore, the aim of this study was to explore miRNA expression difference in normal tissues derived from patients with five different cancer types and identify significant miRNAs regulating pharmacogene expression, using an integrated analysis of miRNA and mRNA. In addition, we purposed to assess miRNA expression difference, in special, in tumor tissues compared with normal tissue of cancer patient samples.

MATERIALS AND METHODS
=====================

miRNA data collection using TCGA datasets
-----------------------------------------

The miRNA data of normal and tumor tissues was downloaded from the TCGA Research Network portal ([cancergenome.nih.gov](cancergenome.nih.gov)) which dataset was available as of May 2016. All data for cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), kidney renal clear cell (KIRC), and lung squamous cell carcinoma (LUSC) samples were collected in the United States, whereas liver hepatocellular carcinoma (LIHC) samples originated from patients in the United States, France, Japan, and China, considering various ethnic backgrounds. The miRNA sequencing (miRNAseq) data was gathered using an Illumina^®^ HiSeq 2000 platform at the Michael Smith Genome Sciences Centre (GSC) of the BC Cancer Agency (Vancouver, BC, Canada). From the Illumina^®^ HiSeq RNASeqV2 level 3 dataset, the "normalized_count" (quantile normalized relative standard error of the mean) value of each miRNA was collected. The miRNAseq data was integrated in to a matrix with log2 transformed for the downstream analysis.

Pharamcogenes selection and mRNA data collection
------------------------------------------------

Important pharmacogenomic-related genes were searched on the Pharmacogenomics Knowledge Base ([@b15-bt-25-482]). Additional pharmacogenetic genes, derived from the U.S. Food and Drug Administration (FDA) Table of Pharmacogenomic Biomarkers in Drug Labels (<http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.html/>), were included. The final phamacogenes for analysis were selected by eliminating duplicates.

The public sequencing data of mRNA, associated with selected pharmacogenes, was also collected from the TCGA Research Network portal. RNA sequencing (RNASeq) data were produced by the University of North Carolina (Chapel Hill, NC, USA) using an Illumina^®^ HiSeq 2000 platform. An mRNAseq matrix with log-2 transformation was made for downstream analysis.

Comparison of miRNA expression in normal and tumor tissues
----------------------------------------------------------

All normal and tumor tissues samples were clustered using a hierarchical method. The clustering dendrogram was drawn using the Ward linkage method. To plot miRNA expression data in a heat map, we selected miRNAs that had \>0.1 deviations in expression levels across samples. In addition, a distance matrix for miRNA expression variables in normal tissue samples was constructed using the Euclidean distance and was visualized by multidimensional scaling (MDS). This step was implemented using cmdscale in the R statistics software package.

Correlation analysis of miRNAs and gene expression
--------------------------------------------------

We selected only paired data in sold primary tumors and normal tissues to compare the difference in expression of miRNA. We analyzed the correlation between the expression levels of miRNA and mRNA in normal tissues of cancer samples and found a significant negative correlation. In addition, the Pearson's correlation analysis was performed to identify in tumor specific downregulated miRNA by analyzing the significant association between miRNA and mRNA expression, and correlation coefficients were calculated with adjustment for cancer types.

miRNA target prediction
-----------------------

We next matched the significant correlations with target information using TargetScan ([@b1-bt-25-482]), miRANDA ([@b4-bt-25-482]), miRDB ([@b34-bt-25-482]), Diana Tools ([@b21-bt-25-482]), miRMap ([@b28-bt-25-482]), and miRNAMap ([@b11-bt-25-482]) as appropriate. Given that no program was consistently superior to the others, and that we aimed to minimize the probability of introducing false positives and/or negatives, we selected genes that were identified by at least three databases as potential targets ([@b7-bt-25-482]). Data extraction and analyses were performed using Python version 3.4 (<http://www.python.org/>).

Evaluation using GEO dataset
----------------------------

For evaluate with our founding, we collected expression datasets of miRNA and mRNA for tumor and non-tumor tissues derived from colonic adenocarcinoma (GSE29623) ([@b5-bt-25-482]) and intrahepatic cholangiocarcinoma and hepatocellular carcinoma patients (GSE57555) ([@b19-bt-25-482]).

Statistical analysis
--------------------

Differences between the number of miRNAs and mRNA expression in each cancer patient were analyzed by Student's *t*-test. Pairwise comparisons of miRNA expression levels in normal tissues were analyzed with a paired *t*-test. Regression analysis tested whether changes in miRNA expression correlated with mRNA expression after adjusted by tissue types. All statistical tests were performed in R Statistics version 3.3.2 (<http://www.r-project.org/>). Statistical significance was defined as a *p*-value of less than 0.05. Multiple testing correction was performed by controlling the false discovery rate ([@b3-bt-25-482]) at α=0.05.

RESULTS
=======

Pharmacogenes selection
-----------------------

Through searching database, 63 genes were selected and 31 genes were added from FDA table. After adding cytochrome P450 oxidoreductase (POR), a total of 95 genes, including 30 drug-metabolizing enzymes and 12 transporter genes, are listed in [Table 1](#t1-bt-25-482){ref-type="table"}.

Comparison of miRNA expression in normal and tumor tissues
----------------------------------------------------------

A total of 1,448 samples were downloaded from the TCGA portal (36 CHOL, 458 COAD, 244 KIRC, 373 LIHC, and 337 LUSC samples). After excluding unpaired data, 1,870 miRNAs remained in 9 CHOL, 8 COAD, 67 KIRC, 48 LIHC, and 43 LUSC primary tumor and paired normal tissue samples. Through Ward linkage analysis, the samples were clustered into one of four major groups that each represented a human tissue ([Fig. 1](#f1-bt-25-482){ref-type="fig"}). The number of mRNAs expressed at lower levels in primary solid tumors was higher than that seen for normal solid tissues ([Table 2](#t2-bt-25-482){ref-type="table"}). Meanwhile, for KIRC and LUSC the number of miRNAs expressed at higher levels in primary solid tumors was lower than that seen for normal solid tissues. The number of miRNAs having lower expression levels in primary tumor tissues was lower than that for normal tissues in patients with CHOL, COAD, and LIHC.

Based on assessment of miRNA relationships among the 95 pharmacogenes in different tissues, the overall pattern of the MDS plot separated the colon, kidney, liver, and lung into four discrete identities, while bile duct tissues were included with the liver ([Fig. 2](#f2-bt-25-482){ref-type="fig"}). A pairwise comparison of miRNA profiles between tissues showed that the profile for normal kidney tissues was closer to that seen for normal colon and lung tissues ([Fig. 3](#f3-bt-25-482){ref-type="fig"}). miRNA expression profiles for bile duct tissues were most similar to those for the liver, which differed most significantly from those seen for the kidney. Of the 1,870 miRNAs analyzed, m*iR-122* exhibited the greatest differences in comparisons between KIRC-LIHC, COAD-LIHC, LIHC-LUSC, CHOL-KIRC, CHOL-LUSC, and CHOL-COAD (*p*=2.08×10^−111^, *p*=6.98×10^−79^, *p*=1.03×10^−62^, *p*=3.52×10^−44^, *p*=3.17×10^−43^, and *p*=2.04×10^−15^, respectively). Similarly, miR-450b, miR-375, miR-590, and miR-26b levels significantly differed among COAD-KIRC (*p*=1.79×10^−60^), KIRC-LUSC (*p*=9.88×10^−55^), COAD-LUSC (*p*=1.03×10^−32^), and CHOL-LIHC (*p*=2.14×10^−11^) comparisons.

Correlation of miRNA and mRNA expression in normal and tumor tissues
--------------------------------------------------------------------

The correlation analysis results showed that 23 miRNAs showed a negative correlation between miRNA and mRNA expression for 14 pharmacogenes ([Table 3](#t3-bt-25-482){ref-type="table"}, [Fig. 4](#f4-bt-25-482){ref-type="fig"}), resulting in 33 combinations of miRNAs and mRNAs. HsamiR-429 decreased 3 mRNA expression levels, including *ADH1B* (*p*=2.48×10^−24^), *AHR* (*p*=1.63×10^−2^), and *ALDH1A1* (*p*=1.44×10^−3^). Meanwhile, hsa-miR-181d decreased the expression levels of *AHR* (*p*=2.88×10^−3^), *BCR* (*p*=6.25×10^−3^), and *CYB5R4* (*p*=6.30×10^−3^), whereas hsa-miR-152 decreased the expression levels of *ABL2* (*p*=1.48×10^−47^), *AHR* (*p*=7.44×10^−8^), and *CYB5R4* (*p*=2.24×10^−45^). Hsa-miR-98 decreased the expression levels of *ADRB2* (*p*=9.13×10^−13^).

The correlation analysis results showed that 19 miRNAs had a negative correlation between miRNA and expression levels of 15 pharmacogene mRNAs ([Table 4](#t4-bt-25-482){ref-type="table"}, [Fig. 5](#f5-bt-25-482){ref-type="fig"}) to yield 24 combinations between miRNAs and mRNAs. Hsa-miR-520b (1.59×10^−3^) decreased *ADRB1* mRNA expression levels, whereas hsa-miR-152 decreased the expression levels of *ABL2* (*p*=1.49×10^−43^), *AHR* (*p*=4.06×10^−19^), and *CYB5R4* mRNA (*p*=1.42×10^−49^). Hsa-miR-98 decreased the expression levels of *ADRB2* mRNA (*p*=1.23×10^−41^).

Evaluation using GEO datasets
-----------------------------

Through evaluation using GSE29623 and GSE57555 datasets, Hsa-miR-520b decreased mRNA expression of *ADRB1*, while hsa-miR-98 decreased mRNA expression of *ADRB2* (*p*\<0.05). Additionally, hsa-miR-152 decreased mRNA expression levels of *ABL2* and *CYB5R4* (*p*\<0.05).

DISCUSSION
==========

In the present study, we used the integrative analysis to identify miRNAs that contribute to altered expression of pharmacogenes in different tissues and tumors. The integrative analysis of mRNA and miRNA expressions is a powerful tool for identifying individual genes and genetic or epigenetic mechanisms of gene expression, as well as a means to understand the relationship between target genes and downstream regulation by miRNA ([@b36-bt-25-482]; [@b37-bt-25-482]). miRNA and mRNA pharmacogene expression was analyzed in paired normal and tumorigenic samples derived from CHOL, COAD, KIRC, LIHC, and LUSC patients using TCGA data.

The data included 95 pharmacogenes that were selected for analysis in our study. For LIHC, drug-metabolizing enzymes and transporters are abundantly expressed in both the liver and bile duct. The colon, kidneys, and lungs are the main organs involved in the elimination of chemotherapeutic drugs. Since lung and colorectal cancer are the first and second leading causes of cancer-related deaths worldwide, respectively ([@b35-bt-25-482]), patients with these types of cancer may receive chemotherapy despite the stage-dependence of these drugs.

The United States has announced a research initiative that aims to accelerate progress toward a new era of precision medicine that is tailored to individuals (<http://www.whitehouse.gov/precisionmedicine/>). Genetic variations and epigenetic changes between individuals may be related to differences in drug responses ([@b9-bt-25-482]). Most previous studies of miRNA in pharmacogenes examined only a limited number of genes with small sample sizes using traditional methods ([@b24-bt-25-482]), such that few global miRNA analyses of pharmacogene expression have been performed ([@b14-bt-25-482]). Our results showed that the number of mRNAs expressed at lower levels in primary solid tumors was higher than that seen for normal solid tissues, while the number of miRNA expression levels of pharmacogenes varied in tumor tissues compared to normal tissues. These results indicate that there are considerable differences in the level and distribution of miRNAs across normal and tumorigenic tissues. However, as expected, our results showed that miRNA and mRNA expression levels were similar between liver and bile duct tissues.

The expression of several drug-metabolizing enzymes and transporter genes was regulated by miRNAs. For example, miR-27a and miR-548a repressed mRNA expression levels of *ABCB1* and *CYP3A4*, respectively ([@b30-bt-25-482]; [@b18-bt-25-482]). Although we found negative correlations of the expression of these miRNAs and mRNAs in our study, they were excluded because their relationships did not occur in more than three miRNA target prediction databases.

Nevertheless, we could use the integrative analysis of massive miRNA-mRNA expression data to identify new various miRNAs for various drug-metabolizing enzyme (*ADH1B, CYB5R4*), receptor (*ADRB1*, *ADRB2*), target (*ABL1*, *ABL2*, *ALOX5*) genes, and transcription factor (*ACE*, *AHR*) that contribute to their differential expression in bile duct, colon, kidney, liver, and lung tissues. Expression of hsa-miR-148 and hsa-miR-152 was reported to be downregulated in gastrointestinal cancer tissues, suggesting that these two miRNAs may be involved during the early stage of gastric carcinogenesis ([@b6-bt-25-482]). The hsa-miR-520 was also decreased in n colorectal carcinoma when compared with normal colorectal tissues ([@b2-bt-25-482]). Associations between these miRNAs and pharmacogenes have not been previously reported. let-7 family members such as let-7, let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, and miR-98 were previously shown to target *ADRB2* ([@b29-bt-25-482]), but to our knowledge this is the first study to show that hsa-miR-98 can also regulate *ADRB2* expression.

Even with targeted therapy, the response to cancer drugs is not solely dependent on tumor epigenetics ([@b20-bt-25-482]). Moreover, germ line epigenetics can play a role in drug effects. Therefore, understanding and considering the contribution of both somatic and germ line epigenetics is important when predicting drug response and toxicity.

Recently, there has been a rapid increase in knowledge of how pharmacogenes are regulated by epigenetic mechanisms and methods to analyze this regulation ([@b16-bt-25-482]). Although we examined a limited set of genes known to be involved in drug responses, the methodology described herein can be easily applied to future studies. One limitation of our study is that we did not stratify the data for age, gender, or racial/ethnic backgrounds, although miRNAs have been shown to exhibit differences related to these parameters ([@b13-bt-25-482]; [@b17-bt-25-482]). miRNAs regulate gene expression by repressing translation and/or by mRNA deadenylation and decay ([@b8-bt-25-482]). Several groups demonstrated that protein repression can occur in the absence of mRNA degradation ([@b33-bt-25-482]), but we did not analyze protein expression levels of the pharmacogenes targeted in our study. Although there are further challenges to defining the role of miRNA in drug responses, here we identified miRNA-mediated changes in pharmacogene expression that may influence therapeutic responses.

In conclusion, epigenomic changes, including miRNA-induced regulation of expression of genes encoding drug-metabolizing enzymes, transporters, or targets, can potentially lead to changes in drug activity that may contribute to drug sensitivity, resistance, and toxicity. Here we investigated miRNA using publicly available epigenomic and transcriptomic databases in an effort to advance pharmacogenomics research. We believe the current analysis will lead to more rapid identification of functional miRNAs that are relevant to understanding variability in drug responses of cancer patients.
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![Heat map representing miRNA levels of normal tissues derived from colon, kidney, liver, and lung cancer patients. The 55 miRNAs have standard deviations \>0.1 across all samples. Each row and column represents a marker and sample, respectively. The clustering dendrogram was drawn using the Ward linkage method.](bt-25-482f1){#f1-bt-25-482}

![Multidimensional scaling analysis plot of normal tissues based on miRNA distance.](bt-25-482f2){#f2-bt-25-482}

![Pairwise comparison of miRNA expression levels in normal tissues. CHOL: cholangiocarcinoma, LIHC: liver hepatocellular cell carcinoma, COAD: colon adenocarcinoma, LUSC: lung squamous cell carcinoma, KIRC: kidney renal clear cell carcinoma.](bt-25-482f3){#f3-bt-25-482}

![Correlation of RNA expression and miRNA changes across normal colon, bile duct, kidney, liver, and lung tissues derived from cancer patients. Line is fitted to the points. Open circle, bile duct; closed circle, kidney; open square, liver; closed square, lung; open triangle, colon (A) correlation of hsa-miR-152 with *ABL2* (*p*=1.48*e*^−47^); (B) correlation of hsa-miR-429 with *ADH1B* (*p*=2.48*e*^−24^); (C) correlation of hsa-miR-98 with *ADRB2* (*p*=9.13*e*^−13^).](bt-25-482f4){#f4-bt-25-482}

![Correlation of RNA expression and miRNA changes across normal and tumor colon, kidney, liver and lung tissues derived from cancer patients. Line is fitted to the points. Open circle, bile duct; closed circle, kidney; open square, liver; closed square, lung; open triangle, colon (A) correlation of hsa-miR-152 with *CYB5R4* (*p*=1.42*e*^−49^); (B) correlation of hsa-miR-98 with *ADRB2* (*p*=1.23*e*^−41^) (C) correlation of hsa-miR-152 with *ABL2* (*p*=1.49*e*^−43^).](bt-25-482f5){#f5-bt-25-482}

###### 

List of 95 pharmacogenes in this study

  Classification         Gene
  ---------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Metabolizing enzymes   *ADH1A, ADH1B, ADH1C, ALDH1A1, COMT, CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP2J2, CYP3A4, CYP3A5, CYP4F2, DPYD, G6PD, GSTP1, GSTT1, NAT1, NAT2, POR, SULT1A1, TPMT, UGT1A1*
  Transporters           *ABCB1, SLC19A1, SLC22A1, SLCO1B1*
  Targets/Pathway        *ABL1, ABL2, ACE, ADRB1, ADRB2, ALK, ALOX5, ASL, ASS1, BCR, BRAF, BRCA1, CFTR, CPS1, CYB5R1, CYB5R2, CYB5R3, CYB5R4, DRD2, EGFR, ERBB2, F2, F5, FIP1L1, HMGCR, HPRT1, IL28B, IL2RA, KCNH2, KCNJ11, KIT, KRAS, LDLR, MS4A1, MTHFR, NAGS, NQO1, NRAS, OTC, P2RY12, P2RY1, PDGFRA, PDGFRB, PGR, PROC, PROS1, PTGIS, PTGS2, SCN5A, SERPINC1, TYMS, VKORC1*
  gDNA repair            *POLG*
  Transcription factor   *AHR, ESR1, NR1I2, PML, RARA, RYR1, VDR*
  Miscellaneous          *HLA-A, HLA-B, HLA-DQA1, HLA-DRB1*

###### 

Comparisons of miRNA and mRNA expression levels between tumors and normal solid tissues derived from cancer patients[^\*^](#tfn1-bt-25-482){ref-type="table-fn"}

  Cancer                                                                    Number of patients                              Number of miRNAs   Number of mRNAs        
  ------------------------------------------------------------------------- ----------------------------------------------- ------------------ ----------------- ---- ----
  Cholangiocarcinoma                                                        9                                               120                82                21   48
  Colon adenocarinoma                                                       8                                               255                120               8    26
  Kidney renal clear cell                                                   67                                              182                270               36   45
  Liver hepatocellular carcinoma                                            48                                              212                168               19   53
  Lung squamous cell carcinoma[^†^](#tfn2-bt-25-482){ref-type="table-fn"}   43[^†^](#tfn2-bt-25-482){ref-type="table-fn"}   157                441               26   42

Significantly differently expressed miRNAs or mRNAs between tumor tissues and normal solid tissues were determined by paired t-test, respectively (*p*\<0.05).

The 36 samples had mRNA expression data.

###### 

miRNA expression negatively correlated with pharmacogene expression in different normal solid tissues derived from cancer patients (*r*^2^\>0.3)

  Classification          Gene           miRNA            FDR adjusted *p*-value   Adjusted Pearson correlation coefficient (*r*^2^)
  ----------------------- -------------- ---------------- ------------------------ ---------------------------------------------------
  Metabolizing enzymes    *ADH1B*        hsa-miR-429      2.48*e*^−24^             0.538
  hsa-miR-577             2.15*e*^−20^   0.468                                     
  *CYB5R4*                hsa-miR-152    2.24*e*^−45^     0.812                    
  hsa-miR-758             1.21*e*^−07^   0.437                                     
  hsa-miR-181d            6.30*e*^−03^   0.361                                     
  Receptors               *ADRB1*        hsa-miR-let-7c   2.39*e*^−05^             0.538
  *ADRB2*                 hsa-miR-98     9.13*e*^−13^     0.738                    
  Targets                 *ABL1*         hsa-miR-378g     1.08*e*^−05^             0.377
  *ABL2*                  hsa-miR-152    1.48*e*^−47^     0.800                    
  hsa-miR-107             6.30*e*^−12^   0.452                                     
  hsa-miR-217             1.96*e*^−09^   0.323                                     
  hsa-miR-410             4.19*e*^−04^   0.317                                     
  *ALOX5*                 hsa-miR-134    1.93*e*^−02^     0.636                    
  Transcription factors   *ACE*          hsa-miR-511      3.92*e*^−09^             0.529
  *AHR*                   hsa-miR-152    7.44*e*^−08^     0.597                    
  hsa-miR-181d            2.88*e*^−03^   0.561                                     
  hsa-miR-429             1.63*e*^−24^   0.643                                     
  hsa-miR-520b            1.22*e*^−03^   0.558                                     
  hsa-miR-653             6.27*e*^−13^   0.630                                     

FDR: false discovery rate.

###### 

miRNA expression negatively correlated with pharmacogene expression in different normal and tumor solid tissues derived from cancer patients (*r*^2^\>0.3)

  Classification         Gene         miRNA          FDR adjusted *p*-value   Adjusted Pearson correlation coefficient (*r*^2^)
  ---------------------- ------------ -------------- ------------------------ ---------------------------------------------------
  Receptors              *ADRB1*      hsa-miR-520b   1.59*e*^−03^             0.450
  *ADRB2*                hsa-miR-98   1.23*e*^−41^   0.450                    
  Targets                *ABL2*       hsa-miR-152    1.49*e*^−43^             0.482
  Metabolizing enzymes   *CYB5R4*     hsa-miR-152    1.42*e*^−49^             0.510

FDR, false discovery rate.
